Skip to content

Individualized Volume of Oral Contrast Agent in CT Enterography

Individualized Volume of Oral Contrast Agent Based on the Clinical Risk Factor in CT Enterography: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03808649
Enrollment
180
Registered
2019-01-17
Start date
2019-01-20
Completion date
2019-07-20
Last updated
2019-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CTE

Brief summary

Small bowel distension is mandatory for the assessment of the bowel wall in CT enterography, but some patients were sufferring inadequate small bowel distension. So, it is important to prescribe personalized regimen according to patient's personal characteristics.

Detailed description

CT enterography has become an important tool in the evaluation of small bowel diseases, especially in patients with inflammatory bowel diseases. Small bowel distension is mandatory for the assessment of the bowel wall. So, it is important to find clinical risk factors for inadequate small bowel distension and prescribe personalized regimen according to patient's personal characteristics to reduce patient acceptance.

Interventions

DRUGdifferent volume of 2.5% mannitol

different volume of 2.5% mannitol based on BMI was used in active comparator group

DRUG1500ml of 2.5% mannitol

1500ml of 2.5% mannitol was used in experimental group

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients undergoing CT enterography

Exclusion criteria

* patients with a history of GI surgery * patients with known or suspected bowel obstruction or perforation * patients with severe chronic renal failure (creatinine clearance\<30 ml/min) * patients with uncontrolled hypertension (systolic blood pressure\>170 mm Hg, diastolic blood pressure\>100 mm Hg) * patients with acute upper GI bleeding * patients with severe inflammatory bowel disease or megacolon * patients with documented allergy to intravascular contrast agent * patients with pregnancy or lactation * patients hemodynamically unstable * patients unable to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Clinical risk factors for inadequate small bowel distention2 monthNumber of clinical risk factors for inadequate small bowel distention
Adequate small bowel distention4 monthThe assessment system includes four parts 1. Whether the contrast reached the caecum is evaluate and recorded as yes or no 2. The overall presence of inhomogeneous contrast is evaluated and recorded as yes or no 3. The maximum dimension of a single loop in each quadrant was recorded. 4. The scale of loops of small bowel distended are evaluated and recorded as 0%-25%,26%-50%,51%-75%,75%-100%

Secondary

MeasureTime frameDescription
Side effects4 monthSide effects in 2 groups The degree of nausea, emesis, diarrhea, abdominal distension and cramp following ingestion are scored on a scale ranging from 0 to 4, in which a higher score represents a higher level of these targets.

Countries

China

Contacts

Primary ContactYanqing Li, PhD, MD
liyanqing@sdu.edu.cn86-531-82169236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026